SCHEMBL20399223

SCHEMBL20399223

CCCS(=O)(=O)Nc1ccc(F)c(C(=O)c2c[nH]c3ncc(-c4ccc(OCC)cc4Cl)cc23)c1F

nearest known ligand 0.76

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
BRAF P15056 3/20 0.76
RIPK2 O43353 2/20 0.76
RAF1 P04049 2/20 0.76
KDR P35968 2/20 0.76
MAP2K2 P36507 2/20 0.76
TGFBR2 P37173 2/20 0.76
NEK2 P51955 2/20 0.76
MAP2K1 Q02750 2/20 0.76
TNK2 Q07912 2/20 0.76
MAP2K5 Q13163 2/20 0.76
PTK6 Q13882 2/20 0.76
NEK11 Q8NG66 2/20 0.76
MAP3K20 Q9NYL2 2/20 0.76
MAP4K5 Q9Y4K4 2/20 0.76
ABCB11 O95342 1/20 0.76
EGFR P00533 1/20 0.76
KRAS P01116 1/20 0.76
PGR P06401 1/20 0.76
RET P07949 1/20 0.76
CHRM2 P08172 1/20 0.76

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20399195 0.95 BRAF (0.75) BRAFRIPK2RAF1KDRMAP2K2
SCHEMBL29796683 0.94 CYP2C9 (0.75) BRAFRIPK2RAF1KDRMAP2K2
SCHEMBL20408837 0.94 CYP2C9 (0.75) BRAFRIPK2RAF1KDRMAP2K2
SCHEMBL20399269 0.94 BRAF (0.73) BRAFRIPK2RAF1KDRMAP2K2
SCHEMBL29725815 0.94 BRAF (0.73) BRAFRIPK2RAF1KDRMAP2K2
SCHEMBL20399230 0.93 BRAF (0.72) BRAFRIPK2RAF1KDRMAP2K2
SCHEMBL20399243 0.93 BRAF (0.72) BRAFRIPK2RAF1KDRMAP2K2
SCHEMBL20399245 0.92 BRAF (0.71) BRAFRIPK2RAF1KDRMAP2K2
SCHEMBL30866600 0.92 BRAF (0.71) BRAFRIPK2RAF1KDRMAP2K2
SCHEMBL20408839 0.92 BRAF (0.79) BRAFRIPK2RAF1KDRMAP2K2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2018134254-A1 PROTEIN KINASE INHIBITORS FOR PROMOTING LIVER REGENERATION OR REDUCING OR PREVENTING HEPATOCYTE DEATH HEPAREGENIX GMBH (DE) 2018-07-26 WO claimed
US-11040027-B2 Protein kinase inhibitors for promoting liver regeneration or reducing or preventing hepatocyte death HEPAREGENIX GMBH (DE) 2021-06-22 US disclosed
US-11040027-B2 Protein kinase inhibitors for promoting liver regeneration or reducing or preventing hepatocyte death HEPAREGENIX GMBH (DE) 2021-06-22 US disclosed
WO-2018134254-A1 PROTEIN KINASE INHIBITORS FOR PROMOTING LIVER REGENERATION OR REDUCING OR PREVENTING HEPATOCYTE DEATH HEPAREGENIX GMBH (DE) 2018-07-26 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11040027-B2 Protein kinase inhibitors for promoting liver regeneration or reducing or preventing hepatocyte death MAPK4, HNF4A, HGF BRAF 113/4885RIPK2 107/4885RAF1 122/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.